First Participant Dosed in Phase I Study of mRNA EBV Vaccine
In a recent press release, the manufacturer, Moderna, announced the first participant has been dosed in the phase I study, known as Eclipse, for the novel vaccine, mRNA-1189, the company's Epstein-Barr virus (EBV) vaccine candidate. Moderna's vaccine candidate against EBV is being developed to prevent EBV-induced infectious mononucleosis and, potentially, EBV infection. Read more.

Study: Effectiveness of COVID-19 Vaccines Over 9 Months in NC
A recent study utilized surveillance data to evaluate the long-term effectiveness of Pfizer, Moderna, and Johnson & Johnson COVID-19 vaccines in preventing SARS-CoV-2 infection, hospitalizations, and deaths. This large study found that the three vaccines, especially the Pfizer and Moderna mRNA vaccines, provided a high degree of protection against severe illness at least 6 months after vaccination. Read more.

Study Explores Homologous and Heterologous COVID-19 Booster Vaccinations
In a recent publication in The New England Journal of Medicine, researchers published data from the ongoing National Institute of Health (NIH)-sponsored trial that resulted in the FDA authorizing the mix-and-match strategy for COVID-19 vaccine boosters last fall. Learn more about what researchers concluded with both homologous and heterologous booster vaccines in the clinical study.